RNF6 promotes the migration and invasion of breast cancer by promoting the ubiquitination and degradation of MST1 Corrigendum in /10.3892/etm.2022.11255

Huang,Yajuan; Zou,Yufeng; Jie,Zhigang

doi:10.3892/etm.2021.11041

RNF6 promotes the migration and invasion of breast cancer by promoting the ubiquitination and degradation of MST1

Corrigendum in: /10.3892/etm.2022.11255

Authors:
- Yajuan Huang
- Yufeng Zou
- Zhigang Jie
View Affiliations

Affiliations: Department of General Surgery, The First Affiliated Hospital of Nanchang University, Nanchang, Jiangxi 330009, P.R. China, Department of Breast Surgery, The Third Hospital of Nanchang, Nanchang, Jiangxi 330006, P.R. China
Published online on: December 6, 2021 https://doi.org/10.3892/etm.2021.11041
Article Number: 118
Copyright: © Huang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Ring finger protein 6 (RNF6), a member of E3 ubiquitin ligases, plays a potential role as a tumour promoter in numerous carcinomas. However, the role and expression of RNF6 in breast cancer (BC) remains to be elucidated. The present study showed that RNF6 upregulation was detected in BC tissues and was associated with short survival in patients with BC. Multivariate analysis also revealed that RNF6 overexpression is an independent predictor for poor outcome of patients with BC. Furthermore, migration and metastasis assay indicated that RNF6 silencing significantly inhibited the invasion and migration of BC cells in vivo and in vitro, and RNF6 suppression decreased YES‑associated protein (YAP) expression. RNF6 promoted the metastatic ability of BC cells via YAP. Mechanistically, RNF6 interacts with mammalian STE20‑like protein kinase 1 (MST1), a key factor that regulates YAP, and promoted its ubiquitination and degradation. Additionally, RNF6 regulated YAP signalling by promoting ubiquitination and degradation of MST1 in BC. Taken together, these data may highlight a role of RNF6 in BC, which could serve as a valuable prognostic indicator and potential therapeutic target for patients with BC.

View Figures

View References

1	Siegel RL, Miller KD and Jemal A: Cancer statistics, 2018. CA Cancer J Clin. 68:7–30. 2018.PubMed/NCBI View Article : Google Scholar
2	Chan BK, Wiseberg-Firtell JA, Jois RH, Jensen K and Audisio RA: Localization techniques for guided surgical excision of non-palpable breast lesions. Cochrane Database Syst Rev. (CD009206)2015.PubMed/NCBI View Article : Google Scholar
3	Sharma R, Sharma R, Khaket TP, Dutta C, Chakraborty B and Mukherjee TK: Breast cancer metastasis: Putative therapeutic role of vascular cell adhesion molecule-1. Cell Oncol (Dordr). 40:199–208. 2017.PubMed/NCBI View Article : Google Scholar
4	Liu L, Zhang Y, Wong CC, Zhang J, Dong Y, Li X, Kang W, Chan FKL, Sung JJY and Yu J: RNF6 promotes colorectal cancer by activating the Wnt/β-catenin pathway via ubiquitination of TLE3. Cancer Res. 78:1958–1971. 2018.PubMed/NCBI View Article : Google Scholar
5	Liang Q, Ma D, Zhu X, Wang Z, Sun TT, Shen C, Yan T, Tian X, Yu T, Guo F, et al: RING-finger protein 6 amplification activates JAK/STAT3 pathway by modifying SHP-1 ubiquitylation and associates with poor outcome in colorectal cancer. Clin Cancer Res. 24:1473–1485. 2018.PubMed/NCBI View Article : Google Scholar
6	Cai J, Xiong Q, Jiang X, Zhou S and Liu T: RNF6 facilitates metastasis and radioresistance in hepatocellular carcinoma through ubiquitination of FoxA1. Exp Cell Res. 374:152–161. 2019.PubMed/NCBI View Article : Google Scholar
7	Xu K, Shimelis H, Linn DE, Jiang R, Yang X, Sun F, Guo Z, Chen H, Li W, Chen H, et al: Regulation of androgen receptor transcriptional activity and specificity by RNF6-induced ubiquitination. Cancer Cell. 15:270–282. 2009.PubMed/NCBI View Article : Google Scholar
8	Lo HS, Hu N, Gere S, Lu N, Su H, Goldstein AM, Taylor PR and Lee MP: Identification of somatic mutations of the RNF6 gene in human esophageal squamous cell carcinoma. Cancer Res. 62:4191–4193. 2002.PubMed/NCBI
9	Qin X, Chen S, Qiu Z, Zhang Y and Qiu F: Proteomic analysis of ubiquitination-associated proteins in a cisplatin-resistant human lung adenocarcinoma cell line. Int J Mol Med. 29:791–800. 2012.PubMed/NCBI View Article : Google Scholar
10	Hippo signaling mediates ferroptosis in malignant mesothelioma. Cancer Discov. 9(1155)2019.PubMed/NCBI View Article : Google Scholar
11	Turunen SP, von Nandelstadh P, Öhman T, Gucciardo E, Seashore-Ludlow B, Martins B, Rantanen V, Li H, Höpfner K, Östling P, et al: FGFR4 phosphorylates MST1 to confer breast cancer cells resistance to MST1/2-dependent apoptosis. Cell Death Differ. 26:2577–2593. 2019.PubMed/NCBI View Article : Google Scholar
12	Gomez M, Kulaberoglu Y and Hergovich A: MST1/2 kinase assays using recombinant proteins. Methods Mol Biol. 1893:319–331. 2019.PubMed/NCBI View Article : Google Scholar
13	Ji XY, Zhong G and Zhao B: Molecular mechanisms of the mammalian Hippo signaling pathway. Yi Chuan. 39:546–567. 2017.PubMed/NCBI View Article : Google Scholar
14	He L, Yuan L, Sun Y, Wang P, Zhang H, Feng X, Wang Z, Zhang W, Yang C, Zeng YA, et al: Glucocorticoid receptor signaling activates TEAD4 to promote breast cancer progression. Cancer Res. 79:4399–4411. 2019.PubMed/NCBI View Article : Google Scholar
15	Tang DE, Dai Y, Lin LW, Xu Y, Liu DZ, Hong XP, Jiang HW and Xu SH: STUB1 suppresseses tumorigenesis and chemoresistance through antagonizing YAP1 signaling. Cancer Sci. 110:3145–3156. 2019.PubMed/NCBI View Article : Google Scholar
16	Chen M, Zhang H, Shi Z, Li Y, Zhang X, Gao Z, Zhou L, Ma J, Xu Q, Guan J, et al: The MST4-MOB4 complex disrupts the MST1-MOB1 complex in the Hippo-YAP pathway and plays a pro-oncogenic role in pancreatic cancer. J Biol Chem. 293:14455–14469. 2018.PubMed/NCBI View Article : Google Scholar
17	Dent P, Booth L, Roberts JL, Liu J, Poklepovic A, Lalani AS, Tuveson D, Martinez J and Hancock JF: Neratinib inhibits Hippo/YAP signaling, reduces mutant K-RAS expression, and kills pancreatic and blood cancer cells. Oncogene. 38:5890–5904. 2019.PubMed/NCBI View Article : Google Scholar
18	Lipkowitz S and Weissman AM: RINGs of good and evil: Ring finger ubiquitin ligases at the crossroads of tumour suppression and oncogenesis. Nat Rev Cancer. 11:629–643. 2011.PubMed/NCBI View Article : Google Scholar
19	Fang S, Lorick KL, Jensen JP and Weissman AM: Ring finger ubiquitin protein ligases: Implications for tumorigenesis, metastasis and for molecular targets in cancer. Semin Cancer Biol. 13:5–14. 2003.PubMed/NCBI View Article : Google Scholar
20	Zhu L, Tong G, Chen J, Wang Y, Wang S, Zhao M, Li J and Ma J: Cloning and identification of a novel RNF6 transcriptional splice variant Spg2 in human development. Sci China C Life Sci. 51:302–307. 2008.PubMed/NCBI View Article : Google Scholar
21	Viale G, Hanlon Newell AE, Walker E, Harlow G, Bai I, Russo L, Dell'Orto P and Maisonneuve P: Ki-67 (30-9) scoring and differentiation of Luminal A- and Luminal B-like breast cancer subtypes. Breast Cancer Res Treat. 178:451–458. 2019.PubMed/NCBI View Article : Google Scholar
22	Chen JY, Lai YS, Chu PY, Chan SH, Wang LH and Hung WC: Cancer-derived VEGF-C increases chemokine production in lymphatic endothelial cells to promote CXCR2-dependent cancer invasion and MDSC recruitment. Cancers (Basel). 11(1120)2019.PubMed/NCBI View Article : Google Scholar
23	Paoletti C, Miao J, Dolce EM, Darga EP, Repollet MI, Doyle GV, Gralow JR, Hortobagyi GN, Smerage JB, Barlow WE and Hayes DF: Circulating tumor cell clusters in metastatic breast cancer patients: A SWOG S0500 translational medicine study. Clin Cancer Res. 25(0208.2019)2019.PubMed/NCBI View Article : Google Scholar
24	D'Agostino L, Nie Y, Goswami S, Tong K, Yu S, Bandyopadhyay S, Flores J, Zhang X, Balasubramanian I, Joseph I, et al: Recycling endosomes in mature epithelia restrain tumorigenic signaling. Cancer Res. 79:4099–4112. 2019.PubMed/NCBI View Article : Google Scholar
25	Salah Z, Melino G and Aqeilan RI: Correction: Negative regulation of the Hippo pathway by E3 ubiquitin ligase ITCH is sufficient to promote tumorigenicity. Cancer Res. 79(3007)2019.PubMed/NCBI View Article : Google Scholar
26	Pan Z, Tian Y, Cao C and Niu G: The emerging role of YAP/TAZ in tumor immunity. Mol Cancer Res. 17:1777–1786. 2019.PubMed/NCBI View Article : Google Scholar
27	Wu J, Minikes AM, Gao M, Bian H, Li Y, Stockwell BR, Chen ZN and Jiang X: Intercellular interaction dictates cancer cell ferroptosis via NF2-YAP signalling. Nature. 572:402–406. 2019.PubMed/NCBI View Article : Google Scholar
28	Gobbi G, Donati B, Do Valle IF, Reggiani F, Torricelli F, Remondini D, Castellani G, Ambrosetti DC, Ciarrocchi A and Sancisi V: The Hippo pathway modulates resistance to BET proteins inhibitors in lung cancer cells. Oncogene. 38:6801–6817. 2019.PubMed/NCBI View Article : Google Scholar
29	Huang W, Hu H, Zhang Q, Wu X, Wei F, Yang F, Gan L, Wang N, Yang X and Guo AY: Regulatory networks in mechanotransduction reveal key genes in promoting cancer cell stemness and proliferation. Oncogene. 38:6818–6834. 2019.PubMed/NCBI View Article : Google Scholar
30	Li JA, Kuang T, Pu N, Fang Y, Han X, Zhang L, Xu X, Wu W, Wang D, Lou W and Rong Y: TRAF6 regulates YAP signaling by promoting the ubiquitination and degradation of MST1 in pancreatic cancer. Clin Exp Med. 19:211–218. 2019.PubMed/NCBI View Article : Google Scholar